BACKGROUND: We evaluated the efficacy of a maternal triple-drug antiretroviral regimen or infant nevirapine prophylaxis for 28 weeks during breast-feeding to reduce postnatal transmission of human immunodeficiency virus type 1 (HIV-1) in Malawi. METHODS: We randomly assigned 2369 HIV-1-positive, breast-feeding mothers with a CD4+ lymphocyte count of at least 250 cells per cubic millimeter and their infants to receive a maternal antiretroviral regimen, infant nevirapine, or no extended postnatal antiretroviral regimen (control group). All mothers and infants received perinatal prophylaxis with single-dose nevirapine and 1 week of zidovudine plus lamivudine. We used the Kaplan-Meier method to estimate the cumulative risk of HIV-1 transmission or death by 28 weeks among infants who were HIV-1-negative 2 weeks after birth. Rates were compared with the use of the log-rank test. RESULTS: Among mother-infant pairs, 5.0% of infants were HIV-1-positive at 2 weeks of life. The estimated risk of HIV-1 transmission between 2 and 28 weeks was higher in the control group (5.7%) than in either the maternal-regimen group (2.9%, P=0.009) or the infant-regimen group (1.7%, P<0.001). The estimated risk of infant HIV-1 infection or death between 2 and 28 weeks was 7.0% in the control group, 4.1% in the maternal-regimen group (P=0.02), and 2.6% in the infant-regimen group (P<0.001). The proportion of women with neutropenia was higher among those receiving the antiretroviral regimen (6.2%) than among those in either the nevirapine group (2.6%) or the control group (2.3%). Among infants receiving nevirapine, 1.9% had a hypersensitivity reaction. CONCLUSIONS: The use of either a maternal antiretroviral regimen or infant nevirapine for 28 weeks was effective in reducing HIV-1 transmission during breast-feeding. (ClinicalTrials.gov number, NCT00164736.) 2010 Massachusetts Medical Society
RCT Entities:
BACKGROUND: We evaluated the efficacy of a maternal triple-drug antiretroviral regimen or infantnevirapine prophylaxis for 28 weeks during breast-feeding to reduce postnatal transmission of human immunodeficiency virus type 1 (HIV-1) in Malawi. METHODS: We randomly assigned 2369 HIV-1-positive, breast-feeding mothers with a CD4+ lymphocyte count of at least 250 cells per cubic millimeter and their infants to receive a maternal antiretroviral regimen, infantnevirapine, or no extended postnatal antiretroviral regimen (control group). All mothers and infants received perinatal prophylaxis with single-dose nevirapine and 1 week of zidovudine plus lamivudine. We used the Kaplan-Meier method to estimate the cumulative risk of HIV-1 transmission or death by 28 weeks among infants who were HIV-1-negative 2 weeks after birth. Rates were compared with the use of the log-rank test. RESULTS: Among mother-infant pairs, 5.0% of infants were HIV-1-positive at 2 weeks of life. The estimated risk of HIV-1 transmission between 2 and 28 weeks was higher in the control group (5.7%) than in either the maternal-regimen group (2.9%, P=0.009) or the infant-regimen group (1.7%, P<0.001). The estimated risk of infantHIV-1 infection or death between 2 and 28 weeks was 7.0% in the control group, 4.1% in the maternal-regimen group (P=0.02), and 2.6% in the infant-regimen group (P<0.001). The proportion of women with neutropenia was higher among those receiving the antiretroviral regimen (6.2%) than among those in either the nevirapine group (2.6%) or the control group (2.3%). Among infants receiving nevirapine, 1.9% had a hypersensitivity reaction. CONCLUSIONS: The use of either a maternal antiretroviral regimen or infantnevirapine for 28 weeks was effective in reducing HIV-1 transmission during breast-feeding. (ClinicalTrials.gov number, NCT00164736.) 2010 Massachusetts Medical Society
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: Athena P Kourtis; Brian Bramson; Charles van der Horst; Peter Kazembe; Yusuf Ahmed; Charles Chasela; Mina Hosseinipour; Rodney Knight; Lebah Lugalia; Gerald Tegha; George Joaki; Robert Jafali; Denise J Jamieson Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2005-07
Authors: Cécile Alexandra Peltier; Gilles François Ndayisaba; Philippe Lepage; Johan van Griensven; Valériane Leroy; Christine Omes Pharm; Patrick Cyaga Ndimubanzi; Olivier Courteille; Vic Arendt Journal: AIDS Date: 2009-11-27 Impact factor: 4.177
Authors: Anna Coutsoudis; Francois Dabis; Wafaie Fawzi; Philippe Gaillard; Geert Haverkamp; D Robert Harris; J Brooks Jackson; Valerie Leroy; Nicolas Meda; Philippe Msellati; Marie-Louise Newell; Ruth Nsuati; Jennifer S Read; Stefan Wiktor Journal: J Infect Dis Date: 2004-05-26 Impact factor: 5.226
Authors: Mina C Hosseinipour; Joep J G van Oosterhout; Ralf Weigel; Sam Phiri; Debbie Kamwendo; Neil Parkin; Susan A Fiscus; Julie A E Nelson; Joseph J Eron; Johnstone Kumwenda Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Denise J Jamieson; Charles S Chasela; Michael G Hudgens; Caroline C King; Athena P Kourtis; Dumbani Kayira; Mina C Hosseinipour; Deborah D Kamwendo; Sascha R Ellington; Jeffrey B Wiener; Susan A Fiscus; Gerald Tegha; Innocent A Mofolo; Dorothy S Sichali; Linda S Adair; Rodney J Knight; Francis Martinson; Zebrone Kacheche; Alice Soko; Irving Hoffman; Charles van der Horst Journal: Lancet Date: 2012-04-26 Impact factor: 79.321
Authors: Valerie L Flax; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Michael G Hudgens; Rodney J Knight; Alice Soko; Denise J Jamieson; Charles M van der Horst; Linda S Adair Journal: J Nutr Date: 2012-05-30 Impact factor: 4.798
Authors: Veronica Escamilla; Carla J Chibwesha; Matthew Gartland; Namwinga Chintu; Mwangelwa Mubiana-Mbewe; Kebby Musokotwane; Patrick Musonda; William C Miller; Jeffrey S A Stringer; Benjamin H Chi Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Elizabeth M Widen; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Valerie L Flax; Athena P Kourtis; Sascha R Ellington; Zebrone Kacheche; Gerald Tegha; Denise J Jamieson; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Matthew G Gartland; Namwinga T Chintu; Michelle S Li; Mwila K Lembalemba; Saziso N Mulenga; Maximillian Bweupe; Patrick Musonda; Elizabeth M Stringer; Jeffrey S A Stringer; Benjamin H Chi Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Charles S Chasela; Athena P Kourtis; Patrick Wall; Jan Drobeniuc; Caroline C King; Hong Thai; Eyasu H Teshale; Mina Hosseinipour; Sascha Ellington; Mary B Codd; Denise J Jamieson; Rod Knight; Patricia Fitzpatrick; Saleem Kamili; Irving Hoffman; Dumbani Kayira; Noel Mumba; Deborah D Kamwendo; Francis Martinson; William Powderly; Chong-Gee Teo; Charles van der Horst Journal: J Hepatol Date: 2013-11-06 Impact factor: 25.083
Authors: Nicole L Davis; William C Miller; Michael G Hudgens; Charles S Chasela; Dorothy Sichali; Dumbani Kayira; Julie A E Nelson; Jeffrey S A Stringer; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Charles van der Horst Journal: AIDS Date: 2014-11-28 Impact factor: 4.177